Condition: Amyotrophic Lateral Sclerosis · Sponsor: Istituto Auxologico Italiano
Individuals with Amyotrophic Lateral Sclerosis (ALS) carrying the C9orf72 HRE mutation (C9Pos) often exhibit different phenotypic traits compared to other patients (C9Neg), presenting a more aggressive form of the disease, with also a higher frequency of comorbidity with frontotemporal dementia (ALS-FTD) and a greater prevalence of family history of ALS and/or other neurodegenerative diseases. Considering these characteristics (comorbidity with FTD and family history of ALS and/or other neurodegenerative pathologies) as factors that have their importance from an assistance point of view, both C9orf72 patients and their caregivers may have particular needs in several respects, and in this sense this investigation is configured. This survey aims to describe the various aspects related to the care and quality of life of C9orf72 ALS patients and their respective caregivers, with the goal of identifying actionable steps to improve the quality of life for both.
This description comes directly from the study's public registry record.
Vincenzo Silani, Prof. · +3902619111 · vincenzo.silani@unimi.it
Luca Grappiolo · +3902619111 · luca.grappiolo@auxologico.it
Always discuss trial participation with your own doctor first.
| Istituto Auxologico Italiano IRCCS | Milan, Lombardy, Italy | Recruiting |
| IRCCS Ospedale San Raffaele | Milan, Italy | Not Yet Recruiting |
| IRCCS Fondazione Mondino, Istituto Neurologico Nazionale a Carattere Scientifico | Pavia, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07302321